

Breast and Cervical Cancer Early Detection Program (BCCP) FY25 BCCP Screening/Referral Form: July 2024 – June 2025

[FORM VALID FOR SCREENING AND REFERRALS/ORDERS FOR 12 MONTHS THROUGH THE END OF MONTH IT EXPIRES. FOR POSSIBLE SHORT-TERM EX		ADDRESS:
CLIENT NAME:	DOB: AGE:	CITY:
ADDRESS: CITY:	ZIP:	
BCCP ENROLLMENT DATE: DATE ENROLLMENT EXPIRES:	PHONE:	PHONE:
ENROLLMENT DATE CORRESPONDS TO DATE SCCP ELIGIBILITY AND CONSENT FORM SIGNED. INSURANCE STATUS: Uninsured (refer to https://www.BeWellNM.com) Underinsured (screening and/or diagnostic services not included in plan		
Hispanic/Latino Origin: ☐ Yes ☐ No (Please identify Hispanic/Latino Origin <u>AND</u> one or	more of the races listed below.)	
Race (check all that apply): American Indian/Alaska Native Asian Black/African Alaska Native		
Preferred Language: ☐ English ☐ Spanish ☐ Navajo ☐ American Sign Languag		
Smoking Status: Never Former Current >>> Referred to cessation services (e.g.,	•	,
BREAST SECTION: For people already <u>known to be at high risk</u> for breast cancer, do breast cancer screening. Those with <u>no personal history</u> of breast cancer should undergo risk		
I. Breast cancer risk status: info at BCCP website: https://www.nmhealth.org/about/phd/pchb/bcc/	CURRENT CLINICAL BREAST EXAM (CBE	
Personal history of breast cancer: no risk assessment is required, and appropriate	CBE Date:	
surveillance guideline should be followed. High If one or more of the items below are true, no further risk assessment is required,	Normal/Benign (includes fibrocystic	o ,
and appropriate high-risk screening recommendation should be followed.	Is today's exam a short-term follow-u ☐ No	p CBE to a previous abnormal CBE?
PRE-menopausal breast cancer among first-degree relative(s) Known genetic mutation such as BRCA 1 or 2 (the person/client or first-degree relative)	☐ Yes >>> Date of previous abnorm	al CBE:
Had radiation treatment to chest between ages 10-30 years		K ON BREAST DIAGRAM TO SHOW LOCATION AND SIZE.
History of lobular neoplasia (LCIS), atypical lobular hyperplasia (ALH), ductal carcino in situ (DCIS), or atypical ductal hyperplasia (ADH)	ma If symptomatic or positive findings, follow	v current NCCN Guidelines® (http://www.nccn.org/) *
Personal or family history of certain genetic syndromes (e.g., Li-Fraumeni)	☐ Palpable mass	
If none of the items above are true, complete a breast cancer risk assessment tool to calculate the person's/client's lifetime risk for developing breast cancer.	☐ Nipple discharge: ☐ Unilateral ☐ B	ilateral \ R L /
Calculated lifetime risk of 20% or more for developing breast cancer based on risk	• Spontaneous? ☐ No ☐ Y	res \
assessment model: LIFETIME RISK =% [enter percentage]	• Expressed on exam? ☐ No ☐ Y	'es \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
☐ <u>Average</u> per risk assessment model; breast cancer risk status should be reassessed periodically (e.g., during enrollment) because average risk status may change over time.	• If yes: Color?	_ {}
Discrete periodically (e.g., during enrollment) because average risk status may change over time. Unknown >> REASON:	Bloody? ☐ No ☐ Yes	$\left\langle \begin{array}{cccccccccccccccccccccccccccccccccccc$
2. Currently lactating (breastfeeding)?	Single Duct? ☐ No ☐ Yes ☐ Asymmetrical thickening or nodularity	Size in R1 R2 R3 R4 L1 L2 L3 L4
3. Breast symptoms reported by client? ☐ No ☐ Yes* >> How Long?		/
If yes, describe:	**	nmend diagnostic evaluation and follow-up for those
a CBE is required to guide potential referral for diagnostic services.	under age 30, the BCC Program cannot	reimburse for these services for average risk people.
PRIOR AUTHORIZATION (PA) REQUIRED FOR: HIGH RISK BREAST CANCER SCREENING (I.E., SC		
DUCTOGRAM, CHEST WALL BIOPSY, AXILLARY LYMPH NODE BIOPSY. PA Date: ERVICAL SECTION: All individuals must be assessed for their cervical car	Approved by: Approved by: Approved by:	at BCC
Cervical cancer risk status: info at BCCP website: https://www.nmhealth.org/about/phd/pchb/bcc/	_	SULTS/INFORMATION: If Pap and/or HPV
☐ High (history of cervical cancer, had in utero DES exposure, and/or is immunocompromised (e.g., HIV positive)	test done, must attach copy of cytology	y report with claim to request reimbursement.
☐ Above Average (patient has history of CIN2 or greater but does not meet "high" risk criteria above) ☐ Average	Pap test done today? ☐ No ☐	Yes >>> Pap Test Date:
☐ Unknown >> REASON:	If yes, is today's Pap test to follow-t	
2. Ever had a Pap test <u>before</u> today? ☐ No	☐No ☐Yes >>> Date of previous	· ————————————————————————————————————
☐ Yes >>> Date of last Pap test: (IF UNSURE OF DATE, MUST PROVIDE BEST GUESS FOR MONTH AND YEAR OF LAST P.	If Pap test <u>not</u> done today, complet AP) □ Not needed □ Done recently	alsowhere
(IF UNSURE OF DATE, MUST PROVIDE BEST GUESS FOR MONTH AND YEAR OF LAST P. 3. Pregnant now? No Year of Last P.	AP) ☐ Not needed ☐ Done recently to ☐ Declined ☐ Needed, not pe	militate cervical caricer screening
4. Hysterectomy? ☐ No ☐ Yes >>> hysterectomy for cervical cancer? ☐ No ☐ Yes		
5. Intact cervix? No Yes	HPV test done today? ☐ No ☐ ☐ If HPV test done today, complete r	
Current USPSTF cervical cancer screening recommendations for average risk women with normal results are: screening with Pap test alone every 3 years for ages 21-65 years; or, for ages 30-65 years,	☐ Co-test (in combination with screening	
screening with high-risk HPV test alone (primary HPV testing) every 5 years, or screening with both a Pap test and HPV test together (co-testing) every 5 years.	☐ Primary Screening	
1 0 (0, 7, 7	Reflex (follow-up after abnormal screen	<u> </u>
PRIOR AUTHORIZATION (PA) REQUIRED FOR: CERVICAL DIAGNOSTIC EXCISIONAL PROCEDURES WHEN PAP TEST RESULT IS NORMAL, AND POST CERVICAL CANCER SURVEILLANCE. PA Date	• • • •	IER EVALUATION OF VISIBLE CERVICAL LESIONS at BCC
Was client enrolled in the BCCP and referred for diagnostic services only?		ENROLLMENT DATE CORRESPONDS TO DATE
REFERRAL/ORDERS: Use the space below to complete referral/orders for additional brea		BCCP ELIGIBILITY AND CONSENT FORM SIGNED
Please bring this form to your appointment(s) listed below.		la(s) cita(s) mencionada(s) debajo.
Referral/Order for: Appointment date:	Referencia/Orden para:	Fecha de la cita:
Time: Facility: Doctor:	Hora: Clínica:	Médico:
Address: Phone:	Dirección:	Teléfono:
Referral/Order for: Appointment date:	Referencia/Orden para:	Fecha de la cita:
Time: Facility: Doctor:	Hora: Clínica:	Médico:
Address: Phone:	Dirección:	Teléfono:

PROVIDER SIGNATURE:__

DATE:

SCREENING CLINIC: